Skip to main content
. 2012 Apr 26;1(2):29–31. doi: 10.1002/cld.18

Figure 2.

Figure 2

SVR rates for patients with IL‐28B genotypes CC, CT, and TT in (A) the ADVANCE trial5 and (B) the SPRINT‐2 trial.6 Abbreviations: BPR, boceprevir and pegylated interferon/ribavirin; BPR48, boceprevir and pegylated interferon/ribavirin for 48 weeks; PR, pegylated interferon/ribavirin; RGT, response‐guided therapy; SPRINT‐2, Serine Protease Inhibitor Therapy 2; T8PR, telaprevir for 8 weeks and pegylated interferon/ribavirin; T12PR, telaprevir for 12 weeks and pegylated interferon/ribavirin.